Stock Insights: Dendreon, Wynn Resorts, Express Scripts, Sequenom, Cognizant May 8th
Dendreon Corp. (NASDAQ:DNDN): BofA/Merrill lowered Dendreon estimates to reflect slower growth trends. Shares are Neutral rated.
Wynn Resorts Ltd. (NASDAQ:WYNN): Credit Suisse said they are looking beyond Q1 results as lower hold in Macau and sluggish Las Vegas results were expected. The firm said Wynn Resort remains well positioned long-term. Shares are Outperform rated with a $166 price target.
Express Scripts Inc. (NASDAQ:ESRX): Credit Suisse expects this weeks earnings call to remove investor uncertainty and said consensus estimates look reasonable. The firm reiterates its Outperform rating and views risk/reward as attractive.
Sequenom Inc. (NASDAQ:SQNM): William Blair believes Sequenom (NASDAQ:SQNM) will still meet and possibly exceed the firm’s 2012 and 2013 targets after Arisoa Diagnostics yesterday morning announced it had partnered with LabCorp’s (NYSE:LH) Genzyme Genetics organization for the sale of the Harmony prenatal test. William Blair thinks Arisoa’s partnership will not have a major impact on Sequenom’s test uptake and keeps an Outperform rating on Sequenom shares.
Cognizant Technology Solutions Corp. (NASDAQ:CTSH): Barclays aid shares of Cognizant were weak on concerns the company will satuarate larger clients. The firm does not believe this is the case and views shares as oversold and reiterates its Overweight rating and $77 price target.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.